Ernst E J
College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA.
Pharmacotherapy. 2001 Aug;21(8 Pt 2):165S-174S. doi: 10.1592/phco.21.12.165s.34509.
Several new antifungal agents, including novel compounds in familiar classes and entirely new classes targeting previously untapped mechanisms, are in various stages of the drug development process. Many new triazole antifungal agents are being studied, including voriconazole, posaconazole, and ravuconazole. The echinocandin antifungals, which represent a new class of antifungal agents, possess activity against a variety of fungal pathogens. The sodarin derivatives and nikkomycins are two additional classes of antifungals in early stages of development; future studies will determine their therapeutic usefulness.
几种新型抗真菌药物正处于药物研发进程的不同阶段,其中包括常见类别中的新型化合物以及针对此前未开发机制的全新类别。许多新型三唑类抗真菌药物正在研究中,包括伏立康唑、泊沙康唑和雷夫康唑。棘白菌素类抗真菌药代表了一类新型抗真菌药物,对多种真菌病原体具有活性。索达林衍生物和多氧霉素是另外两类处于研发早期阶段的抗真菌药;未来的研究将确定它们的治疗效用。